Patents by Inventor Xin GAN
Xin GAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240269276Abstract: The present invention relates to a specific binding protein targeting PD-L1 and CD73, wherein the specific binding protein is capable of specifically binding to PD-L1 and/or a fragment thereof, and CD73 and/or a fragment thereof. The present invention further relates to use of the specific binding protein in the treatment, prevention and/or diagnosis of diseases such as immune diseases, acute and chronic inflammatory diseases, and tumor diseases.Type: ApplicationFiled: May 24, 2022Publication date: August 15, 2024Inventors: Qianqian Shan, Xuekun Zhang, Xin Gan, Haishan Luo, Lei Shi, Yongqiang Wang, Xingxing Jia, Rongchao Wang, Yiping Rong
-
Publication number: 20240270847Abstract: Provided are a method for depleting regulatory T cells (Tregs) and/or increasing the proportion of CD8+ T cells/Tregs in a subject, a method for treating a refractory cancer in a subject, a combination therapy for treating a cancer, a method for reducing side effects of treating a cancer using a CTLA4 antibody, a method for implementing long-term administration or administration when necessary for a cancer patient, an administration method for an anti-CTLA-4 single heavy chain antibody, a unit dose composition, the use of an anti-CTLA-4 single heavy chain antibody in preparation of a drug, a method for determining the administration dose of an anti-tumor drug, and a method for determining the administration form of an anti-tumor drug.Type: ApplicationFiled: April 20, 2022Publication date: August 15, 2024Applicant: HARBOUR BIOMED (SHANGHAI) CO., LTD.Inventors: Xin GAN, Jinfeng XIANG, Xiaolu TAO, Jinfeng JI, Xiaoxiang CHEN
-
Publication number: 20240228635Abstract: Involved is an isolated antigen binding protein, being capable of binding CCR8 derived from a primate animal. Further involved are a pharmaceutical composition comprising the antigen binding protein, and an application of the antigen binding protein and/or the pharmaceutical composition in the prevention and/or treatment of a tumor or a cancer.Type: ApplicationFiled: August 27, 2021Publication date: July 11, 2024Applicant: B7 THERAPEUTICS INC.Inventors: Shuang LU, Yongqiang WANG, Xin GAN, Fei CHEN, Jinqiu HE, Xiaohui SHAO, Shaoping HU, Chuchu ZHAO, Jiuqiao ZHAO, Yiping RONG
-
Publication number: 20240132603Abstract: Involved is an isolated antigen binding protein, being capable of binding CCR8 derived from a primate animal. Further involved are a pharmaceutical composition comprising the antigen binding protein, and an application of the antigen binding protein and/or the pharmaceutical composition in the prevention and/or treatment of a tumor or a cancer.Type: ApplicationFiled: August 26, 2021Publication date: April 25, 2024Applicant: HARBOUR BIOMED US, INC.Inventors: Shuang LU, Yongqiang WANG, Xin GAN, Fei CHEN, Jinqiu HE, Xiaohui SHAO, Shaoping HU, Chuchu ZHAO, Jiuqiao ZHAO, Yiping RONG
-
Publication number: 20240034792Abstract: Provided are an antigen binding protein capable of binding to PD-1 and a fusion protein thereof, and corresponding preparation method therefor and the use thereof. The fusion protein is capable of targeting PD-1 and CD73.Type: ApplicationFiled: July 15, 2021Publication date: February 1, 2024Inventors: Haishan LUO, Qianqian SHAN, Yongqiang WANG, Xuekun ZHANG, Lei SHI, Yun ZHANG, Chuchu ZHAO, Wei ZHOU, Xin GAN
-
Publication number: 20240010721Abstract: The present invention discloses an ROR1-targeted antibody or an antigen-binding fragment thereof, a preparation method therefor and use thereof, wherein the ROR1-targeted antibody or the antigen-binding fragment thereof comprises a VL and a VH; the VL comprises the following CDRs or mutations thereof: VL CDR1, VL CDR2 and VL CDR3 as set forth in SEQ ID NOs: 69, 78 and 84, respectively; the VH comprises the following CDRs or mutations thereof: VH CDR1, VH CDR2 and VH CDR3 as set forth in SEQ ID NOs: 12, 33 and 53, respectively. The antibody or the antigen-binding fragment thereof described above has good binding affinity to ROR1, has almost no cross-reactivity with ROR2, has a KD value comparable to that of the reference antibody in the prior art, has a significant endocytosis effect, and has an ADCC effect in tumor cells.Type: ApplicationFiled: September 2, 2021Publication date: January 11, 2024Inventors: Zheng WANG, Yongqiang WANG, Xin GAN
-
Publication number: 20230357425Abstract: Provided an isolated antigen binding protein having one or more of the following properties: a. capable of binding to both human CD73 and Cynomolgus monkey CD73; b. capable of inhibiting 5?ectonucleotidase activity of CD73; c. capable of mediating CD73 internalization; d. capable of promoting T cell proliferation; e. with a relatively stable concentration in serum; and f. capable of inhibiting tumor growth and/or tumor cell proliferation. In addition, provided a method for producing the isolated antigen binding protein as well as pharmaceutical uses of the isolated antigen binding protein in preventing, alleviating and/or treating tumor.Type: ApplicationFiled: August 20, 2020Publication date: November 9, 2023Applicant: Harbour BioMed (Shanghai) Co., LtdInventors: Lei SHI, Xin GAN, Qianqian SHAN, Yiping RONG, Yun HE
-
Publication number: 20230242658Abstract: The present invention discloses a 4-1BB-binding protein and use thereof. The 4-1BB-binding protein comprises a heavy chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, wherein the HCDR1 comprises a sequence as set forth in SEQ ID NO: 15 or a variant 1 thereof, or SEQ ID NO: 16; the HCDR2 comprises a sequence selected from SEQ ID NO: 60 or a variant 2 thereof, and SEQ ID NO: 50 or a variant 4 thereof; the HCDR3 comprises a sequence as set forth in SEQ ID NO: 103 or a variant 3 thereof, SEQ ID NO: 333 or a variant 5 thereof, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 116, SEQ ID NO: 326, SEQ ID NO: 331, SEQ ID NO: 334 or SEQ ID NO: 96. The 4-1BB-binding protein of the present invention is a fully human antibody having the binding activity to human 4-1BB and cynomolgus monkey 4-1BB. Some 4-1BB-binding proteins are only half the size of conventional IgG antibodies; they can be well used for bispecific antibodies.Type: ApplicationFiled: June 29, 2021Publication date: August 3, 2023Applicant: NONA BIOSCIENCES (SUZHOU) CO., LTD.Inventors: Lei SHI, Bing HUANG, Yun HE, Xin GAN, Fei CHEN, Jianxun ZHAO, Bo XIANG
-
Publication number: 20230068048Abstract: Provided are a residence time determination method and apparatus, an edge computing device, and a storage medium. The method includes that: a player image that is collected by an image collection apparatus and includes a specified part of a game player is acquired, and the image collection apparatus is deployed in a game area; identification information of the game player is determined on the basis of the feature information of the specified part in the player image; and the residence time of the game player in the game area is determined on the basis of the identification information of the game player and the existence time of the feature information of the game player in the game image.Type: ApplicationFiled: September 29, 2021Publication date: March 2, 2023Inventors: Jiacheng WU, Dongliang SUN, Shuai ZHANG, Jinliang LIN, Xin GAN
-
Publication number: 20220414372Abstract: Provided are a scene detection method and apparatus, an electronic device and a computer storage medium. The method includes: own device running data and scene information collected by a collection device are acquired through an own first detection system component; the device running data and the scene information are made pulled to a cloud for the cloud to detect itself and the collection device; in a case of a detection exception of the cloud, an own first device state is detected according to the device running data, and a second device state of the collection device is detected based on the scene information; and in a case where both the first device state and the second device state are normal, a scene state is detected according to a present frame of scene image in the scene information and a locally stored configuration file to obtain a detection result for use.Type: ApplicationFiled: June 30, 2021Publication date: December 29, 2022Inventors: Jiacheng WU, Shual Zhang, Jiriliang Lin, Xin Gan
-
Publication number: 20220411513Abstract: Provided is an anti-PD-L1 antigen binding protein, capable of binding to primate-derived PD-L1 with a KD value of 1×10?8 M or less. The antigen binding protein can block the binding of PD-1 and CD80 to PD-L1, stimulate the secretion of cytokines in immune cells, and can inhibit tumor growth and/or tumor cell proliferation. Also provided is a fusion protein, comprising human TGFBRII or a fragment thereof and the antigen binding protein. Also provided is an application of the antigen binding protein and/or the fusion protein in the prevention and treatment of tumors or cancers.Type: ApplicationFiled: September 29, 2020Publication date: December 29, 2022Applicant: Harbour BioMed (Shanghai) Co., LtdInventors: Yun HE, Shuwen REN, Bin LIU, Xin GAN, Donghai LI, Fei CHEN, Ling WANG, Jin LI, Yiping RONG
-
Publication number: 20220406125Abstract: The embodiments of the disclosure provide a game state detection and configuration updating method and apparatus, a device and a storage medium. The method includes that: description information of multiple configuration files of a first game table is acquired from a cloud; first description information is determined from the description information of the multiple configuration files, the version of a first configuration file described by the first description information being higher than that of a first local configuration file of the corresponding first game table; the first configuration file is acquired from the cloud to update the first local configuration file; and a game state of the first game table is detected according to the updated first local configuration file, as well as a first image collected for the first game table. The disclosure improves the accuracy of game state detection and the efficiency of configuration updating.Type: ApplicationFiled: June 30, 2021Publication date: December 22, 2022Inventors: Jiacheng WU, Shuai ZHANG, Gan XIAO, Xin GAN, Wenxuan WU
-
Publication number: 20220284904Abstract: In one embodiment, a method includes presenting a text message comprising n-grams via a user interface of a client system based on a user utterance received at the client system, receiving a first user request at the client system to edit the text message, presenting the text message visually divided into blocks via the user interface, wherein each block comprises one or more of the n-grams of the text message and the n-grams in each block are contiguous with respect to each other and grouped within the block based on an analysis of the text message by a natural-language understanding (NLU) module, receiving a second user request at the client system to edit one or more of the blocks, and presenting an edited text message generated based on the second user request via the user interface.Type: ApplicationFiled: August 20, 2021Publication date: September 8, 2022Inventors: Yiming Pu, Gabrielle Catherine Moskey, Christopher E Balmes, Justin Denney, Xin Gan, Ilana Orly Shalowitz
-
Publication number: 20220002414Abstract: Disclosed are isolated monoclonal antibodies, comprising a CD152-binding domain, wherein the antibodies bind specifically to human CD152. Methods of making and using the antibodies to treat diseases including cancers and autoimmune diseases are also provided.Type: ApplicationFiled: July 14, 2021Publication date: January 6, 2022Applicant: Harbour BioMed (Shanghai) Co., Ltd.Inventors: Xin GAN, Yun HE, Yuqiang SHEN, Jiuqiao ZHAO, Yiping RONG, Frank Grosveld, Dubravka Drabek, Marinus (Rien) Van Haperen, Rick Janssens
-
Patent number: 11098122Abstract: Disclosed are isolated monoclonal antibodies, comprising a CD152-binding domain, wherein the antibodies bind specifically to human CD152. Methods of making and using the antibodies to treat diseases including cancers and autoimmune diseases are also provided.Type: GrantFiled: December 19, 2018Date of Patent: August 24, 2021Assignee: HARBOUR BIOMED (SHANGHAI) CO., LTD.Inventors: Xin Gan, Yun He, Yuqiang Shen, Jiuqiao Zhao, Yiping Rong, Frank Grosveld, Dubravka Drabek, Marinus (Rien) Van Haperen, Rick Janssens
-
Publication number: 20190202914Abstract: Disclosed are isolated monoclonal antibodies, comprising a CD152-binding domain, wherein the antibodies bind specifically to human CD152. Methods of making and using the antibodies to treat diseases including cancers and autoimmune diseases are also provided.Type: ApplicationFiled: December 19, 2018Publication date: July 4, 2019Inventors: Xin GAN, Yun HE, Yuqiang SHEN, Jiuqiao ZHAO, Yiping RONG